XML 123 R103.htm IDEA: XBRL DOCUMENT v3.25.0.1
Product Revenue - Product Sales (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues      
Product revenue - net $ 3,810,241 $ 2,458,779 $ 1,415,921
Product revenue, net      
Revenues      
Product revenue - gross 4,786,744 2,718,969 1,438,440
Less: Rebates and sales returns (1,007,198) (529,117) (183,828)
Product revenue - net 3,779,546 2,189,852 1,254,612
Product revenue, net | BRUKINSA®      
Revenues      
Product revenue - net 2,644,226 1,290,396 564,651
Product revenue, net | Tislelizumab      
Revenues      
Product revenue - net 620,836 536,620 422,885
Product revenue, net | XGEVA®      
Revenues      
Product revenue - net 224,403 92,828 63,398
Product revenue, net | BLINCYTO®      
Revenues      
Product revenue - net 74,331 54,342 36,107
Product revenue, net | KYPROLIS®      
Revenues      
Product revenue - net 66,171 39,799 13,696
Product revenue, net | POBEVCY®      
Revenues      
Product revenue - net 53,509 56,547 38,124
Product revenue, net | REVLIMID®      
Revenues      
Product revenue - net 36,028 76,018 79,049
Product revenue, net | Other      
Revenues      
Product revenue - net $ 60,042 $ 43,302 $ 36,702